Immunology / Virology & Vaccines

#Immunology / Virology & Vaccines #University of Turku

Vaccines trigger rapid lymph node responses, study finds

Vaccines trigger a notably rapid response in the stromal cells of draining lymph nodes within the first hours after administration.   Researchers at the University of Turku and the InFLAMES Flagship in Finland also discovered that the stromal alterations prime the lymph node landscape for the subsequent steps… Read More

#News

#Eye health #Immunology / Virology & Vaccines #LIfT BioSciences #mRNA

New DDW Highlights podcast: 11 August 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In the week that the US… Read More

#News

#Clinical trials #Diabetes #Duchenne muscular dystrophy #HIV #Immunology / Virology & Vaccines #Obesity #Oncology

This week in drug discovery (4-8 August) 

News round-up for 4-8 August by DDW Senior Digital Content Editor Diana Turner. In the week that the US Department of Health and Human Services cancelled multiple programmes investigating mRNA vaccines, a number of other clinical trials have made the headlines. The top stories:… Read More

#News

Vaccine production
#Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines #United States

US cancels mRNA vaccine development contracts

The US Department of Health and Human Services (HHS) has announced the beginning of a “coordinated wind-down” of its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority (BARDA).   The department says the decision follows a comprehensive review of mRNA-related investments initiated during the… Read More

#News #Trending News

Older adult receiving vaccine
#Dementia #GSK #Immunology / Virology & Vaccines #Neuroscience #Shingles

RWD shows shingles vaccine reduces dementia risk

GSK presented six abstracts at the Alzheimer’s Association International Conference (AAIC), including real-world data which shows an association between recombinant zoster vaccine (RZV) and potential reduced risk of dementia.  Tony Wood, Chief Scientific Officer, said: “Building on our expertise in immunology and inflammation, we’re using advanced technology… Read More

#News #Trending News

Monkeypox virus
#CEPI #Immunology / Virology & Vaccines #Pandemic prevention #Vaccines

Immune marker playbooks support vaccine development

CEPI and PATH are joining forces to create playbooks that map all available research into specific immune markers that indicate protection against target viruses with epidemic or pandemic potential.  Supported by $8 million in funding from CEPI, these research and development (R&D) manuals could hold important insights… Read More

#News

Vaccine
#Immunology / Virology & Vaccines #Mergers and acquisitions #Sanofi #Vicebio

Sanofi acquires vaccine biotech Vicebio for $1.6 billion

Vicebio has agreed to be acquired by Sanofi for a total of $1.6 billion, including an upfront payment of $1.15 billion as well as development and regulatory milestones payments of $450 million.  Vicebio was created by Medicxi to develop vaccines for respiratory viruses utilising its proprietary Molecular… Read More

#Business & Investment #News

#Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines #United States

Medical societies sue RF Kennedy Jr for “unlawful” vaccine changes

A group of medical professional societies have filed a lawsuit against Robert F Kennedy Jr in the US District Court for the District of Massachusetts to defend vaccine policy, and to put an end to what they call the Secretary’s “assault on science, public health and evidence-based medicine”. … Read More

#News #Trending News

mRNA
#Adaptvac #Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines #University of Copenhagen

Virus-like particles enhance effect of mRNA vaccines

Researchers from Denmark have demonstrated that a simple addition to mRNA vaccines can significantly enhance their effectiveness.  mRNA technology is highly effective against viruses and quick to adapt to new variants, but the immunity tends to wane rapidly, leaving people vulnerable to reinfection just months after vaccination. Read More

#Editor's Choice #News

#Adaptvac #CEPI #Disease X #Ebola virus #Immunology / Virology & Vaccines #Pandemic prevention

All-in-one vaccine development backed by $12.4m funding

Scientists at Denmark’s Adaptvac will lead the development of a new vaccine that could provide all-in-one protection against multiple deadly viruses, including Ebolavirus Zaire, Sudan Ebolavirus and Marburg.  Backed by $12.4 million of funding from CEPI and the European Union’s Horizon Europe programme, a global consortium led… Read More

#Editor's Choice #News

Mosquito
#Collaboration #Immunology / Virology & Vaccines #Malaria #Recipharm #University of Oxford

Research partners advance two malaria vaccine candidates

The University of Oxford and ReciBioPharm, Recipharm’s Advanced Biologics division, are expanding their long-standing collaboration with the development of two blood-stage malaria vaccine candidates for Phase I/II clinical trials.   Since 2016, the collaboration has delivered five vaccine candidates and will now actively progress the manufacture of R78C… Read More

#News

Covid-19
#Covid-19 #Immunology / Virology & Vaccines #Preclinical development #Rocketvax #SARS-CoV-2

Robust preclinical results for live-attenuated SARS-CoV-2 vaccine

Live-attenuated SARS-CoV-2 vaccine candidate, OTS-228, has demonstrated exceptional safety, efficacy, and genomic stability in preclinical animal models.  The vaccine was developed under the scientific leadership of Professor Dr Volker Thiel, Chief Scientist of Rocketvax and Professor of Virology at the University of Bern.  The latest… Read More

#News #Trending News

#Cancer research #Cancer vaccines #Collaboration #Immunology / Virology & Vaccines #NHS Cancer Vaccine Launch Pad #Scancell Holdings

In Conversation With: Phil L’Huillier, Scancell

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Phil L’Huillier, CEO of… Read More

#Cancer Research #News

Close up of vaccine syringe
#Bacteria #Immunology / Virology & Vaccines #University of Oxford #Viral vectors

Gene-based vaccine shows promise in early-stage trial

Trial results have revealed encouraging results for a new vaccine targeting group B meningococcus (MenB) and established that a gene-based vaccine platform can induce protective antibody responses against bacteria.  The investigational vaccine, ChAdOx1 MenB.1, developed by researchers at the University of Oxford, was shown to be safe… Read More

#News #Trending News

#Collaboration #Immunology / Virology & Vaccines #Longevity #Partnership #Protein chemistry / Proteomics #RNA sequencing

New DDW Highlights podcast: 22 April 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week of financial uncertainty for the industry, our round-up focuses on the… Read More

#News

Preparing Covid-19 vaccine for injection
#Immunology / Virology & Vaccines #Pandemic response #University of Queensland #Vaccine candidate #virus

Queensland researchers attempt 150-day vaccine challenge

Queensland researchers are attempting to create a vaccine in just 150 days to prove how far their response capabilities to a viral pandemic have come since Covid-19.  The clock started on 10 February 2025 for The University of Queensland’s Vaccine Rapid Response Team, which has been tasked… Read More

#News #Trending News